Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer

SIMPLE SUMMARY: Historically, the treatment of prostate cancer was a blanket approach for all. Prostate cancer has not benefitted from targeted treatments based on specific tumour characteristics (ie. Particular genetic or molecular patterns) the way other cancers have. This is important as studies...

Descripción completa

Detalles Bibliográficos
Autores principales: McNevin, Ciara S., Cadoo, Karen, Baird, Anne-Marie, Murchan, Pierre, Sheils, Orla, McDermott, Ray, Finn, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616097/
https://www.ncbi.nlm.nih.gov/pubmed/34830851
http://dx.doi.org/10.3390/cancers13225697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616097/
https://www.ncbi.nlm.nih.gov/pubmed/34830851
http://dx.doi.org/10.3390/cancers13225697

Ejemplares similares